These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2009215)

  • 1. Immunotoxins.
    Press OW
    Biotherapy; 1991; 3(1):65-76. PubMed ID: 2009215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
    van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
    Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical construction of immunotoxins.
    Ghetie V; Vitetta ES
    Mol Biotechnol; 2001 Jul; 18(3):251-68. PubMed ID: 11503519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
    Webb KS; Poulton SH; Liberman SN; Walther PJ
    J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
    Theuer CP; Pastan I
    Am J Surg; 1993 Sep; 166(3):284-8. PubMed ID: 8368439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted toxin therapy for the treatment of cancer.
    FitzGerald D; Pastan I
    J Natl Cancer Inst; 1989 Oct; 81(19):1455-63. PubMed ID: 2550658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
    Ramakrishnan S; Houston LL
    Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
    Laske DW; Ilercil O; Akbasak A; Youle RJ; Oldfield EH
    J Neurosurg; 1994 Mar; 80(3):520-6. PubMed ID: 8113865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
    Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC
    J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotoxins: the role of the toxin.
    Antignani A; Fitzgerald D
    Toxins (Basel); 2013 Aug; 5(8):1486-502. PubMed ID: 23965432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxin-labeled monoclonal antibodies.
    Kreitman RJ
    Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.
    Weidle UH; Tiefenthaler G; Schiller C; Weiss EH; Georges G; Brinkmann U
    Cancer Genomics Proteomics; 2014; 11(1):25-38. PubMed ID: 24633317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.